Biased Ligands. Better Drugs.

Press Releases

5/2/16 - Trevena Announces Successful End-of-Phase 2 Meeting with FDA and Outlines Phase 3 Program for Oliceridine

Trevena, Inc. today announced the successful completion of the End-of-Phase 2 Meeting process with the United States Food and Drug Administration (FDA). The company has reached general agreement with the FDA on key elements of the Phase 3 program to support a New Drug Application (NDA) for oliceridine (TRV130), to which the FDA has granted Breakthrough Therapy designation. Read More

4/15/16 - Trevena Announces BLAST-AHF Phase 2b Trial Results will be Presented at the Heart Failure 2016 Conference
Trevena, Inc. today announced that results from its BLAST-AHF Phase 2b study of TRV027 in acute heart failure (AHF) will be presented at Heart Failure 2016, the annual congress of the Heart Failure Association of the European Society of Cardiology. Read More

4/7/16 - Trevena to Present at the Needham & Company 15th Annual Healthcare Conference
Trevena, Inc. today announced that the company will be webcasting its corporate presentation at the Needham & Company 15th Annual Healthcare Conference on Wednesday, April 13, 2016 at 10:00 a.m. EDT in New York. Read More

3/31/16 - Trevena Announces Presentations at the 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting
Trevena, Inc. today announced that the Company will present four posters at the 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting. The poster presentations highlight data from the oliceridine program, including key data from the Company’s Phase 2b trial in acute pain following abdominoplasty. Read More

3/9/16 - Trevena Reports Full Year 2015 Financial Results
Trevena, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2015 and provided an update regarding its ongoing clinical programs. Read More

3/3/16 - Trevena to Present at Three Upcoming Investor Events in March
Trevena, Inc. today announced that the company will be presenting at the Cowen 36th Annual Health Care Conference in Boston, the 28th Annual ROTH Conference in Orange County, and the Barclays Global Healthcare Conference in Miami. Read More

3/2/16 - Trevena to Host Conference Call on March 9th to Discuss Full Year 2015 Financial Results
Trevena, Inc. today announced that it will host a conference call on Wednesday, March 9, 2016 at 7:30 a.m. Eastern Time to discuss financial results as of and for the year ended December 31, 2015, as well as 2015 and recent corporate highlights. Read More

2/22/16 - Trevena, Inc. Receives FDA Breakthrough Therapy Designation for Oliceridine
Trevena, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to the Company's lead product candidate, intravenous oliceridine (TRV130), for the management of moderate-to-severe acute pain. Read More

2/17/16 - Trevena to present at the 2016 RBC Capital Markets' Global Healthcare Conference
Trevena, Inc. (NASDAQ: TRVN), today announced that David Soergel, M.D., its chief medical officer, will present a company overview and update at the 2016 RBC Capital Markets' Global Healthcare Conference on Tuesday, February 23, 2016 at 2:05 p.m. EST in New York. Read More

2/3/16 - Trevena to present at the 18th Annual BIO CEO & Investor Conference
Trevena, Inc. today announced that the company will be webcasting its corporate presentation at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016 at 4:30 p.m. EST in New York. Read More

1/19/16 - Trevena, Inc. Announces Initiation of Oliceridine Phase 3 Clinical Program
Trevena, Inc., today announced the launch of the oliceridine (TRV130) Phase 3 clinical program with the enrollment of patients in the open label Phase 3 ATHENA-1 study. Read More

12/16/15 - Trevena, Inc. added to NASDAQ Biotechnology Index (NBI)
Trevena, Inc., today announced that it has been selected for addition to the NASDAQ Biotechnology Index®. The selection will become effective upon market open on Monday, December 21, 2015. Read More

12/3/15 - Trevena Announces FDA Grant of Fast Track Designation to Oliceridine (TRV130)
Trevena, Inc. (NASDAQ: TRVN), today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to oliceridine (TRV130) for the management of moderate-to-severe acute pain. Read More

12/3/15 - Trevena Granted Key Composition of Matter and Use Patent for TRV027 in Europe
Trevena, Inc. (NASDAQ: TRVN), today announced that the European Patent Office has granted European Patent EP2376101B1, “Beta-Arrestin Effectors and Compositions and Methods of Use Thereof,” which covers the composition of matter for TRV027 and uses thereof. Read More

12/2/15 - Trevena to present at the Oppenheimer 26th Annual Healthcare Conference
Trevena, Inc. (NASDAQ: TRVN), today announced that the company will be webcasting its corporate presentation at the Oppenheimer 26th Annual Healthcare Conference on Tuesday, December 8, 2015 at 1:00 p.m. EST in New York. Read More

11/12/15 - Trevena CEO to present at the Jefferies 2015 Global Healthcare Conference
Trevena, Inc. (NASDAQ: TRVN), today announced Maxine Gowen, Ph.D., its chief executive officer, will present a company overview at the Jefferies 2015 Global Healthcare Conference on Thursday November 19, 2015 at 3:20 p.m. GMT (10:20 a.m. EST) in London. Read More

11/10/15 - Trevena Reports Third Quarter 2015 Financial Results and Provides Corporate Update
Trevena, Inc. (NASDAQ: TRVN), today announced financial results for the quarter ended September 30, 2015 and provided an update regarding its ongoing clinical programs. Read More

News Archive

Copyright © Trevena, Inc.